Nicole Pezzino, PharmD, BCACP, BC-ADM, CDCES, details how pharmacies can utilize the booming GLP-1 medication class for greater revenue opportunities.
|Slideshows|October 15, 2019
- Drug Topics October 2019
- Volume 163
- Issue 10
5 New Diabetes Technologies and Treatments
Author(s)Drew Boxler
Noteworthy diabetes management products and updates making waves this year.
Advertisement
Like other areas of healthcare, diabetes management in 2019 has been experiencing a combination of new device developments and improvements, technological advancements, new drug approvals, and new partnerships offering a glimpse of distant future possibilities. Here are five noteworthy products and updates that are making waves in the diabetes management space this year:
Articles in this issue
almost 7 years ago
The Truth About Statinsalmost 7 years ago
Opinion: Color Coded Inhalersalmost 7 years ago
Pharmacist Collaborations Must Extend to Dentistsalmost 7 years ago
Contemplating the Future of List Pricesalmost 7 years ago
New Drug Review: Tafamidis Meglumine for Cardiomyopathyalmost 7 years ago
Life-Altering Gene Therapy Pipeline Poses Challengesalmost 7 years ago
Solving the Drug Shortage Burdenalmost 7 years ago
Providing Healthcare to Transgender Patientsalmost 7 years ago
State Laws May Determine Access to Pharmacy-based PrEP Clinicsabout 7 years ago
Official CVS/Aetna Merger: Greater Convenience, Less Cost ReformAdvertisement
Related to this article
Detailed phase 3 data show retatrutide lowered body weight and A1C over 80 weeks for patients with diabetes and obesity.
In a rapidly evolving diabetes and obesity management landscape, Brian Smith, PharmD, discusses approaches that are helping patients maximize their outcomes on GLP-1 therapy.
Pharmacists can improve cardiometabolic adherence by easing adverse effects, simplifying regimens, tackling costs, and synchronizing refills.
In this episode, our hosts examine the expanding role of incretin therapies in children and adolescents with obesity and type 2 diabetes.
GLP-1 adherence requires integrated care teams, administrative technology, and proactive clinical support to tackle complex challenges.
Medicaid and Part D low-income subsidy enrollment narrowed some gaps, but much of the disparity occurred within the same plans.
A modeling study projects that a structured lifestyle program for adults with prediabetes would be cost-effective and likely cost saving.
Advertisement
Advertisement